⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
Global Perfusion Systems Market to Register Incremental Growth at a CAGR of ~5% by 2034 | DelveInsight
globenewswire.com
MDT
LIVN
BSX
THC
AMGN
AZN
PFE
JNJ
MRNA
BMY
GILD
REGN
TEVA
CL
PG
KO
PEP
DIS
NVDA
GOOG
AMZN
MSFT
AAPL
TSLA
META
CRM
ADBE
NFLX
INTC
AMD
QCOM
CMCSA
T
VZ
IBM
ORCL
CSCO
ACN
HON
GE
BA
CAT
XOM
CVX
JPM
BAC
WFC
C
GS
MS
AXP
V
MA
HD
MCD
SBUX
COST
WMT
TGT
LOW
CVS
UNH
CI
ETSY
ROKU
PYPL
MELI
EBAY
BABA
JD
PDD
NTES
BIDU
TM
SONY
SAP
AIR
ASML
BNTX
NVO
BP
FCX
BHP
RIO
VALE
NKE
LULU
UA
CROX
NOC
GD
LMT
RTX
AVGO
AMAT
LRCX
MU
NXPI
MRVL
SNPS
CDNS
VRTX
BIIB
LLY
ABBV
MRK
CHTR
CMG
SIRI
GEHC
GSK
SNY
MREO
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
globenewswire.com
REGN
AAFA Highlights New Resources for Nasal Polyps in Recognition of Global CRSwNP Awareness Day
globenewswire.com
AMGN
AZN
SNY
REGN
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
globenewswire.com
REGN
SNY
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
globenewswire.com
REGN
SNY
Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight
globenewswire.com
AZN
CRSP
NKTR
INCY
IPHA
ABBV
BIIB
ALKS
IMVT
CLRB
IMPP
REGN
THO
AUTL
KYMR
CBIO
GILD
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
globenewswire.com
REGN
THE SKIN OF COLOR SOCIETY (SOCS) SUCCESSFULLY PRESENTS LANDMARK SYMPOSIUM CHAMPIONING EVIDENCE-BASED DERMATOLOGY AND COLLABORATION
prnewswire.com
ABBV
JNJ
ARQT
BMY
LLY
INCY
SNY
REGN
PFE
UCB
BIIB
ORGN
TAK
ELMD
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & Outlook
globenewswire.com
JNJ
AMGN
GMAB
ABBV
AZN
PFE
BMY
REGN
XNCR
ZYME
Regeneron Announces Investor Conference Presentations
globenewswire.com
REGN